{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:39:17Z","timestamp":1770741557738,"version":"3.49.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["11\/92\/15"],"award-info":[{"award-number":["11\/92\/15"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The Baby-OSCAR trial is a multi-centre, randomised, placebo-controlled parallel group trial of early treatment of large patent ductus arteriosus (PDA) with ibuprofen in extremely preterm infants. This paper describes the statistical analysis plan for the short-term health outcomes of the Baby-OSCAR trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and design<\/jats:title>\n                <jats:p>This is a randomised controlled trial to determine if early-targeted treatment of a large PDA with parenteral ibuprofen in extremely preterm babies improves short and long-term health and economic outcomes. Infants born between 23<jats:sup>+0<\/jats:sup> and 28<jats:sup>+6<\/jats:sup> weeks of gestation, confirmed by echocardiography as having a large PDA (with a diameter of at least 1.5\u2009mm and unrestricted pulsatile PDA flow pattern), with parental informed consent, were randomly allocated to receive either ibuprofen or placebo within 72\u2009h of birth. The primary outcome is a composite of death by 36\u2009weeks\u2019 postmenstrual age or moderate or severe bronchopulmonary dysplasia (BPD) at 36\u2009weeks\u2019 postmenstrual age.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Baseline demographic and clinical characteristics will be described by randomised group. The primary analysis will be on the modified intention to treat (ITT) population. Counts and percentages will be presented for binary and categorical variables, and mean and standard deviation or median and interquartile range will be presented for continuous variables. For binary outcomes, risk ratios and confidence intervals will be calculated using log binomial or Poisson regression with a robust variance estimator. Continuous outcomes will be analysed using linear regression models, or quantile regression models if skewed. Analyses will be adjusted for all minimisation factors where technically possible, and correlation between siblings from multiple births will be accounted for by nesting the clusters as a random effect. Both crude and adjusted effect estimates will be presented, with the primary inference based on the adjusted estimates. Ninety-five per cent confidence intervals will be used for all pre-specified outcome comparisons.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This paper describes the statistical analysis plan for short-term health outcomes of the trial, including the analysis principles, definitions of important outcomes, methods for primary analysis, pre-specified subgroup analysis, and secondary analysis. The plan was finalised prior to completion of short-term follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ISRCTN registry <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.isrctn.com\/ISRCTN84264977\">ISRCTN84264977<\/jats:ext-link>. Registered on 15 September 2010.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-021-05324-3","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T17:03:33Z","timestamp":1622048613000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Baby-OSCAR: Outcome after Selective early treatment for Closure of patent ductus ARteriosus in preterm babies\u2014a statistical analysis plan for short-term outcomes"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9571-0715","authenticated-orcid":false,"given":"Jennifer L.","family":"Bell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmund","family":"Juszczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pollyanna","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Linsell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,26]]},"reference":[{"issue":"1","key":"5324_CR1","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12887-021-02558-7","volume":"21","author":"S Gupta","year":"2021","unstructured":"Gupta S, et al. Study protocol: baby-OSCAR trial: Outcome after Selective early treatment for Closure of patent ductus ARteriosus in preterm babies, a multicentre, masked, randomised placebo-controlled parallel group trial. BMC Pediatr. 2021;21(1):100. https:\/\/doi.org\/10.1186\/s12887-021-02558-7.","journal-title":"BMC Pediatr"},{"issue":"23","key":"5324_CR2","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1001\/jama.2017.18556","volume":"318","author":"C Gamble","year":"2017","unstructured":"Gamble C, Krishan A, Stocken D, Lewis S, Juszczak E, Dor\u00e9 C, et al. Guidelines for the content of statistical analysis plans in clinical trials. JAMA. 2017;318(23):2337\u201343. https:\/\/doi.org\/10.1001\/jama.2017.18556.","journal-title":"JAMA"},{"issue":"1","key":"5324_CR3","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1542\/peds.2008-2418","volume":"123","author":"S Noori","year":"2009","unstructured":"Noori S, McCoy M, Friedlich P, Bright B, Gottipati V, Seri I, et al. Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. Pediatrics. 2009;123(1):e138\u201344. https:\/\/doi.org\/10.1542\/peds.2008-2418.","journal-title":"Pediatrics"},{"issue":"2","key":"5324_CR4","doi-asserted-by":"publisher","first-page":"F94","DOI":"10.1136\/adc.2007.120584","volume":"93","author":"BH Su","year":"2008","unstructured":"Su BH, Lin HC, Chiu HY, Hsieh HY, Chen HH, Tsai YC. Comparison of ibuprofen and indometacin for early-targeted treatment of patent ductus arteriosus in extremely premature infants: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2008;93(2):F94\u20139. https:\/\/doi.org\/10.1136\/adc.2007.120584.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"3","key":"5324_CR5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1159\/000345337","volume":"103","author":"MY Oncel","year":"2013","unstructured":"Oncel MY, Yurttutan S, Degirmencioglu H, Uras N, Altug N, Erdeve O, et al. Intravenous paracetamol treatment in the management of patent ductus arteriosus in extremely low birth weight infants. Neonatology. 2013;103(3):166\u20139. https:\/\/doi.org\/10.1159\/000345337.","journal-title":"Neonatology"},{"issue":"26","key":"5324_CR6","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJM200106283442602","volume":"344","author":"B Schmidt","year":"2001","unstructured":"Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, Saigal S, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med. 2001;344(26):1966\u201372. https:\/\/doi.org\/10.1056\/NEJM200106283442602.","journal-title":"N Engl J Med"},{"key":"5324_CR7","unstructured":"Neonatal Survey Database from the Trent Region. 2010 []; Available from: http:\/\/www.le.ac.uk\/departments\/health-sciences\/research\/timms\/projects\/tns."},{"issue":"mar23 1","key":"5324_CR8","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340(mar23 1):c332. https:\/\/doi.org\/10.1136\/bmj.c332.","journal-title":"BMJ"},{"key":"5324_CR9","doi-asserted-by":"crossref","unstructured":"Parry G, et al. CRIB II: an update of the clinical risk index for babies score. Lancet. 2003;361(9371):1789\u201391.","DOI":"10.1016\/S0140-6736(03)13397-1"}],"updated-by":[{"DOI":"10.1186\/s13063-021-05409-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000}}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05324-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-021-05324-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05324-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T09:12:41Z","timestamp":1631178761000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-021-05324-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5324"],"URL":"https:\/\/doi.org\/10.1186\/s13063-021-05324-3","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13063-021-05409-z","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,26]]},"assertion":[{"value":"29 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13063-021-05409-z","URL":"https:\/\/doi.org\/10.1186\/s13063-021-05409-z","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Baby-OSCAR received approval from the MHRA, the NHS Health Research Authority, and East Midlands \u2013 Nottingham 2 Research Ethics Committee:  on 16 December 2014 (REC ref.: 14\/EM\/0172). Trust Confirmation of Capacity and Capability was obtained at each site. The Chief Investigator or delegate will submit an Annual Progress Report, End of Study Notification, and Final Report to the Funder; NIHR HTA, MHRA, REC, HRA, host organisation and Sponsor. The trial is sponsored by the University of Oxford.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SG is a member of the steering committee of the ESPR NPE (Neonatologist Performed Echocardiography). EJ was a member of the NIHR HTA General Board from 2016 to 2017 and the NIHR HTA Commissioning Board from 2013 to 2016. PH is currently a member of the NIHR HTA Commissioning Board. EJ, JB, LL and PH report receipt of funding from NIHR, outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"368"}}